Citations

Abstract Introduction Remote cognitive assessments offer an accessible, scalable way to support clinical characterization and longitudinal monitoring of cognition. This study evaluates the feasibility of implementing Mayo Test Drive (MTD), a remote, self-administered digital cognitive assessment, within a specialized clinic focused on eligibility assessments for anti-amyloid therapies for Alzheimer’s disease (AD). Method Two-hundred and nine ( N =209) patients (M age =71.2, 53% female) were evaluated through the Mayo Clinic Rochester Alzheimer’s Disease Treatment Clinic (ADTC) and had the opportunity to complete MTD, either as a remote, patient-initiated session through a patient-facing healthcare portal or during an in-clinic neuropsychological evaluation. Results Clinical diagnoses included 55.2% mild cognitive impairment (MCI), 31.0% mild dementia, and 11.6% moderate dementia, in addition to 2.2% cognitively unimpaired (CU), as determined by neurology consensus at a multidisciplinary case conference. Among those who initiated MTD ( n =197/209), 97.5% completed a session (70.6% remotely, 26.9% in clinic). Completion rates were high across diagnostic groups and did not significantly differ by clinical severity ( p =.12): CU (100%), MCI (99.1%), mild dementia (97.0%), and moderate dementia (89.5%). Remote completion rates overall were high (97.9%). Among completers, administration setting (remote vs. in-clinic) did not significantly differ by clinical stage, χ²(3)=2.37, p =.49. Reasons for non-initiation included not receiving or opening portal messages and other/unknown factors. Discussion Remote digital cognitive assessment is feasible within the context of clinic eligibility evaluations for AD therapies. The high completion rates of MTD across clinical impairment levels in this setting support development of paths for broader use in cognitive characterization in AD care.

Abstract Background Individuals with coexisting Alzheimer's disease (AD) and disorders of CSF dynamics such as normal‐pressure hydrocephalus (NPH) have lower CSF Aβ42 levels, which can confound interpretation of AD CSF‐biomarkers. However, little is known about how CSF dynamics influences plasma AD biomarkers. The objective of this study was to determine whether mass spectrometry‐based blood tests for AD are associated with disproportionately enlarged subarachnoid space hydrocephalus (DESH) on MRI. Method 509 Individuals from the Mayo Clinic Study of Aging, with MRI, 11C‐Pittsburgh compound B (Aβ) PET scans, and plasma phosphorylated‐tau protein 217, Aβ40 and Aβ42 were included. We performed an age‐adjusted logistic regression to determine whether abnormal values of p ‐Tau 217 (Abnormal if >1.55 pg/mL), %p‐tau217 defined as the ratio of phosphorylated Tau217 to non‐phosphorylated tau x 100% (Abnormal if >1.55%), Aβ42 (Abnormal if <41.5 pg/mL), and Aβ42/40 ratio (Abnormal if <0.094) were associated with the presence of DESH, as classified by a previously validated automated algorithm. Result Thirty‐two participants were classified as DESH‐positive. The median [IQR] age was 76.8 yrs [70.6, 82.9] for participants with DESH and 72.4 [59.3, 85.5] without DESH (Table 1). An abnormal plasma Aβ42 was associated with DESH (OR, 2.56 [1.19, 5.74], p = 0.018), but having an abnormal Aβ42/40 ratio (OR 2.01 [0.94, 4.56], p = 0.079) was not. There was no association between being DESH‐positive and an abnormal plasma p ‐tau217 (OR 1.30 [0.51, 3.09], p = 0.560) or with abnormal %plasma p ‐tau217 (OR 1.82 [0.74, 4.20], p = 0.17) (Figure 1). Subgroup analysis showed that only those participants who had an abnormal Aβ42 and positive amyloid PET (≥25 Centiloids) showed an association with DESH compared to biomarker‐ and PET‐negative participants (OR 3.10 [1.15, 8.43], p = 0.024 ) . Conclusion Understanding how CSF dynamics affect plasma biomarkers is critical for implementation. The relationship between lower Aβ42 and DESH is expected based on prior CSF studies, which can be addressed by using an amyloid ratio. p ‐tau217 shows robustness against DESH, making it a suitable biomarker in cases of abnormal cerebrospinal fluid dynamics although validation in a more severe CSF dynamics group is warranted.

AbstractBackgroundThere is increasing need for noninvasive biomarkers of Alzheimer’s Disease (AD) neuropathologic change for early detection and intervention through risk‐factor modification and disease‐modifying therapies. One such biomarker is the prediction of chronological age from routine clinical tests such as an electrocardiogram (EKG) to discriminate between observed biological age from chronological age for healthy aging. Deviation of true age from predicted age has been associated with heart failure, hypertension, and coronary heart disease. However, the association between EKG‐based age and underlying neuropathology has not been studied.MethodWe used a cohort of 336 participants from the Mayo Clinic Study of Aging, a population‐based prospective study of residents in Olmsted County, Minnesota, with antemortem EKG and post‐mortem brain autopsy (Table 1 & 2). Age was predicted from EKG using a validated convolutional neural network algorithm. We used ordinal logistic regression to identify associations between lower neuropathologic scores of AD (Thal phase, neuritic plaque score, Braak stage, and overall AD neuropathologic change) and the Age‐Gap, defined as EKG‐predicted age minus chronological age. Results were controlled for true age, sex, and APOE e4 carrier status. Neuropathologic scales were grouped into none, low, intermediate, and high categories. Observations were weighted by the inverse of years between last EKG and time of death to account for the time difference between acquisition of EKG and autopsy.ResultWe found that an increasing Age‐Gap (i.e. older predicted age) was inversely associated with lower overall AD neuropathologic change (OR 0.93 [0.89, 0.97], p = 0.002). Investigation of the components of AD neuropathologic change showed that an increasing Age‐Gap was also inversely associated with lower amyloid metrics such as Thal phase (OR 0.85 [0.80, 0.89], p < 0.001) and neuritic plaque scores (OR 0.91 [0.87, 0.96], p < 0.001), but not tau metrics like Braak staging (OR 1.05 [1.00, 1.10], p = 0.05).ConclusionIn this work, we show that older predicted age on EKG, a noninvasive biomarker associated with vascular and biological aging, is associated with higher amyloid burden and neuropathologic change of AD.

AbstractBackgroundPlasma biomarkers for Alzheimer’s disease (AD) such as phosphorylated tau protein 181 (p‐tau 181), neurofilament light chain (NfL), amyloid‐β 42/40 ratio (Aβ42/40), and glial fibrillary acidic protein (GFAP) have shown high performance in the discrimination of those with clinical mild cognitive impairment (MCI) or dementia from cognitively unimpaired individuals, but few population‐based autopsy studies have evaluated the neuropathological correlates of plasma biomarkers.MethodWe utilized a population‐based prospective study of 350 participants with autopsy and antemortem plasma biomarker data. Plasma biomarkers Aβ42/40 ratio, p‐tau181, GFAP, and NfL were measured using Quanterix Simoa assays. We predicted AD neuropathological change (ADNC), Braak staging, and neuritic plaque score using these plasma biomarkers and investigated the added utility of cognitive and demographic information. We utilized a variable selection procedure in cross‐validated (CV) logistic regression models by minimizing the Bayesian Information Criterion to identify the best set of predictors for a given outcome among plasma biomarkers, demographic variables, and neuropsychological tests included in the Mayo Clinic Preclinical Alzheimer Cognitive Composite (Mayo‐PACC).ResultADNC was best predicted with plasma GFAP, NfL, p‐tau181 biomarkers along with APOE ε4 carrier status and Mayo‐PACC cognitive score (CV AUC = 0.821). Braak staging was best predicted using plasma GFAP, p‐tau181, and cognitive scores (CV AUC = 0.788). Neuritic plaque score was best predicted using plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL biomarkers (CV AUC = 0.778). Inclusion of plasma biomarkers demonstrated significantly better prediction of Braak staging (p<0.01) and neuritic plaque score (p<0.01), but not ADNC (p = 0.13), when compared to models that included only cognitive and demographic information. Univariate models consistently underperformed in comparison to multivariate models.ConclusionPlasma biomarkers can provide valuable predictive information about the presence of AD pathology, which can facilitate earlier recognition and diagnosis of AD. Incorporation of demographic and cognitive variables along with plasma variables in multivariable models will improve prediction accuracy of AD pathology, specifically Braak staging and ADNC.

Abstract Pleomorphic xanthoastrocytomas (PXAs) are rare primary brain tumors that mainly affect children and young adults. We report a case of recurrent PXA in an adult and review the literature. To our knowledge, this is the first adult report highlighting clinical, CSF, and imaging findings of recurrent PXA with leptomeningeal spread. A 60-year-old woman presented with a 2-month history of fluctuating mental status, aphasia, low-back pain, progressive paraparesis, and urinary retention. She was previously diagnosed with a left temporal PXA 17 years prior and underwent gross total resection with no evidence of tumor recurrence for the next several years. Approximately 10 months prior to her current presentation, she was found to have radiographic recurrence of the left temporal PXA. She underwent gross total resection, with final pathology revealing anaplastic transformation, WHO grade 3, BRAF V600E mutation positive. She next underwent photon radiotherapy, and chemotherapy with temozolomide. She had good clinical and radiographic response to treatment for 8 months prior to developing her current symptomatology. MRI of the brain and spine showed local recurrence with new diffuse contrast enhancement of the spinal cord and nerve roots. Cerebrospinal fluid (CSF) analysis showed a total nucleated cell count of 10/mcL, protein &gt;1250 mg/dL, glucose &lt; 20 mg/dL, and xanthochromia. CSF cytology was positive for malignant cells consistent with PXA. Although PXA is often associated with a favorable prognosis, recurrence with anaplastic transformation can be associated with dissemination throughout the nervous system and worse outcomes. Despite the rarity of such cases, clinicians should remain vigilant, especially when anaplastic transformation occurs. Early detection of leptomeningeal involvement through thorough CSF analysis and appropriate imaging can facilitate prompt intervention and potentially improve patient outcomes.

We report a case highlighting key clinical, CSF, and imaging findings of recurrent pleomorphic xanthoastrocytoma with leptomeningeal spread.